Claims for Patent: 4,189,469

Summary for Patent: 4,189,469

Title:	Pharmaceutical compositions
Abstract:	A pharmaceutical composition for oral administration in dosage unit form which comprises at least one xanthine derivative selected from the group consisting of (a) (.omega.-1(-hydroxyalkyl-dialkylxanthines wherein the (.omega.-1)-hydroxyalkyl group contains 5 or 6 carbon atoms and is in the 1- or 7-position, the alkyl group in the other of the 1- and 7-position contains from 1 to 12 carbon atoms and the alkyl group in the 3-position contains from 1 to 4 carbon atoms, (b) (.omega.-1)-oxoalkyl-dimethylxanthines wherein the (.omega.-1)-oxoalkyl group contains 5 or 6 carbon atoms and is in the 1- or 7-position, (c) dimethylxanthine derivatives having an additional alkyl group containing from 4 to 12 carbon atoms in the 1- or 7-position, and (d) dimethylxanthine derivatives having an additional benzyl group in the 1- or 7-position and a saliva forming agent, each dosage unit containing at least 300 mg of xanthine derivative, and the weight ratio of xanthine derivative to saliva forming agent being in the range from 1:2 to 10:1 and a method for the preparation of said composition.
Inventor(s):	Gleixner; Klaus (Taunusstein-Wehen, DE), Muller; Roland (Wiesbaden, DE), Lehrach; Franz (Wiesbaden, DE)
Assignee:	Hoechst Aktiengesellschaft (Frankfurt, DE)
Application Number:	05/683,795
Patent Claims:	1. An orally-administrable pharmaceutical composition in unit-dosage form which comprises an amount of pharmaceutically-active component having a degree of gastro-intestinal-tract incompatibility which renders it unsafe for oral administration in combination with a sufficient amount of swelling agent to reduce such incompatibility to a level at which the unit dosage is safe for oral administration. 2. A pharmaceutical composition as claimed in claim 1 for oral administration in dosage unit form which comprises at least one xanthine derivative selected from the group consisting of (a) (107 -1)-hydroxyalkyl-dialkylxanthine wherein the (.omega.-1)-hydroxyalkyl group contains 5 to 6 carbon atoms and is in the 1- or 7-position, the alkyl group in the other of the 1- and 7-positions contains from 1 to 12 carbon atoms, and the alkyl group in the 3-position contains from 1 to 4 carbon atoms, (b) (.omega.-1)-oxoalkyl-dimethylxanthine wherein the (.omega.-1)-oxoalkyl group contains 5 to 6 carbon atoms and is in the 1- or 7-position, (c) dimethylxanthine derivative having an additional alkyl group containing from 4 to 12 carbon atoms in the 1- or 7-position, and (d) dimethylxanthine derivative having an additional benzyl group in the 1- or 7-position and a swelling agent, each dosage unit containing at least 300 mg of xanthine derivative, and the weight ratio of xanthine derivative to swelling agent being in the range from 1:2 to 10:1. 3. A composition as claimed in claim 2 wherein the xanthine derivative is water-soluble. 4. A composition as claimed in claim 2 wherein each dosage unit contains at least 400 mg of xanthine derivative. 5. A composition as claimed in claim 2 wherein each dosage unit contains up to 1200 mg of an (.omega.-1)-oxoalkyl-dimethylxanthine. 6. A composition as claimed in claim 2 wherein the xanthine derivative comprises 1-(5-oxohexyl)-3,7-dimethylxanthine or 7-(5-oxohexyl)-1,3-dimethylxanthine. 7. A composition as claimed in claim 2 wherein the swelling agent is a member selected from the group consisting of guar powder, galacto-mannane, an alginate, an acrylic acid powder and a cellulose derivative. 8. A composition as claimed in claim 2 which additionally contains a further excipient selected from the group consisting of polyvinyl pyrrolidone, polyvinyl acetate, talcum and magnesium stearate. 9. A composition as claimed in claim 2 in tablet form. 10. A pharmaceutical composition as claimed in claim 2 wherein the xanthine derivative is in admixture with the swelling agent. 11. A composition as claimed in claim 2 wherein the xanthine derivative is 1-(5-hydroxyhexyl)-3,7-dimethylxanthine. 12. A composition as claimed in claim 2 wherein the xanthine derivative is 7-(5-hydroxyhexyl)-1,3-dimethylxanthine. 13. A pharmaceutical composition as claimed in claim 2, which is safe for oral administration in dosage unit form and wherein the xanthine derivative is (a). 14. A pharmaceutical composition as claimed in claim 2, which is safe for oral administration in dosage unit form and wherein the xanthine derivative is (b). 15. A pharmaceutical composition as claimed in claim 2, which is safe for oral administration in dosage unit form and wherein the xanthine derivative is (c). 16. A pharmaceutical composition as claimed in claim 2, which is safe for oral administration in dosage unit form and wherein the xanthine derivative is (d). 17. In a method for preparing a pharmaceutical composition in oral dosage form with a pharmaceutically-active component having a degree of gastro-intestinal-tract incompatibility which renders in unsafe for oral administration, the improvement which comprises admixing the pharmaceutically-active component with a sufficient amount of swelling agent to reduce such incompatibility to a level at which the pharmaceutical composition is safe for oral administration. 18. In a method for preparing a pharmaceutical composition in oral unit-dosage form with a pharmaceutically-active component having a degree of gastro-intestinal-tract incompatibility which renders it unsafe for oral administration in excess of a particular unit dosage, the improvement which comprises admixing a higher unit dosage of the pharmaceutically-active component with a sufficient amount of swelling agent to reduce such incompatibility to a level at which the oral unit-dosage form with the higher unit dosage is safe for oral administration.